Ms Danielle Lang

Ms Danielle Lang

Research Academic

School of Medicine and Public Health (Clinical Pharmacology and Clinical Toxicology)

Career Summary

Biography

Danielle is the director of the Newcastle Evaluation Group, which provides expert clinical and economic analysis to the Commonwealth Government to inform decisions regarding new medicines for the Pharmaceutical Benefits Scheme. Danielle first joined the Newcastle Evaluation Group as a health economist in 1998 and has gained extensive experience in economic modelling. Danielle has had a key role in developing economic evaluation teaching materials for the World Health Organization and has delivered these through short courses in low and middle income countries including South Africa, Hungary, Turkey, Thailand, Jordan and Uganda. Danielle has had reports of her scholarly work published in journals such as the Lancet and PLOS Medicine. She currently teaches post-graduate health economics and economic evaluation at the Centre for Clinical Epidemiology and Biostatistics.


Qualifications

  • Post Graduate Diploma in Health Economics and Eval, Monash University
  • Bachelor of Mathematics/Bachelor of Economics, University of Newcastle

Keywords

  • economic evaluation
  • economic modelling
  • health economics
  • pharmacoeconomics

Fields of Research

Code Description Percentage
110399 Clinical Sciences not elsewhere classified 100

Professional Experience

UON Appointment

Title Organisation / Department
Research Academic University of Newcastle
School of Medicine and Public Health
Australia
Senior Lecturer University of Newcastle
School of Medicine and Public Health
Australia

Teaching

Code Course Role Duration
PUBH6260 Clinical Economics
The University of Newcastle
Course coordinator 1/07/2003 - 19/09/2015
PUBH6250 Health Economics
The University of Newcastle
Course Coordinator 1/01/2004 - 19/09/2015
PUBH6290 Economic evaluation of health care
University of Newcastle
(previously PUBH6260 Clinical Economics)
Course Coordinator 1/07/2015 - 19/09/2015
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (8 outputs)

Year Citation Altmetrics Link
2015 Lang DL, Zhao FL, Robertson J, 'Prevention of postpartum haemorrhage: Cost consequences analysis of misoprostol in low-resource settings', BMC Pregnancy and Childbirth, (2015) [C1]

© 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organizatio... [more]

© 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization Model List of Essential Medicines for use in the prevention of postpartum haemorrhage (PPH) in low-resource settings. This study evaluates the costs and health outcomes of use of oral misoprostol to prevent PPH in settings where injectable uterotonics are not available. Methods: A cost-consequences analysis was conducted from the international health system perspective, using data from a recent Cochrane systematic review and WHO's Mother-Baby Package Costing Spreadsheet in a hypothetical cohort of 1000 births in a mixed hospital (40 % births)/community setting (60 % births). Costs were estimated based on 2012 US dollars. Results: Using oxytocin in the hospital setting and misoprostol in the community setting in a cohort of 1000 births, instead of oxytocin (hospital setting) and no treatment (community setting), 22 cases of PPH could be prevented. Six fewer women would require additional uterotonics and four fewer women a blood transfusion. An additional 130 women would experience shivering and an extra 42 women fever. Oxytocin/misoprostol was found to be cost saving (US$320) compared to oxytocin/no treatment. Conclusions: Our findings confirm that, even though misoprostol is not the optimum choice in the prevention of PPH, misoprostol could be an effective and cost-saving choice where oxytocin is not or cannot be used due to a lack of skilled birth attendants, inadequate transport and storage facilities or where a quality assured oxytocin product is not available. These benefits need to be weighed against the large number of additional side effects such as shivering and fever, which have been described as tolerable and of short duration.

DOI 10.1186/s12884-015-0749-z
Citations Scopus - 2Web of Science - 1
2007 Salkeld G, Henry DA, Hill SR, Lang DL, Freemantle N, D'Assuncao J, 'What drives health-care spending priorities? An international survey of health-care professionals', Plos Medicine, 4 256-259 (2007) [C1]
DOI 10.1371/journal.pmed.0040094
Co-authors Mddah01
2003 Henry DA, Lang DL, 'Published pharmacoeconomic analyses: science or marketing?', Internal Medicine Journal, 33 404-404 (2003) [C3]
Co-authors Mddah01
2003 Lang DL, Lopert R, Hill SR, 'Use of pharmacoeconomics in prescribing research. Part 5: modelling - beyond clinical trials', JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 28 433-439 (2003)
DOI 10.1046/j.1365-2710.2003.00458.x
Citations Scopus - 12Web of Science - 10
2003 Lopert R, Lang DL, Hill SR, 'Use of pharmacoeconomics in prescribing research. Part 3: cost-effectiveness analysis - a technique for decision-making at the margin', Journal of Clinical Pharmacy and Therapeutics, 28 243-249 (2003) [C1]
DOI 10.1046/j.1365-2710.2003.00465.x
Citations Scopus - 7Web of Science - 6
2003 Robertson J, Lang DL, Hill SR, 'Use of pharmacoeconomics in prescribing research. Part 1: costs - moving beyond the acquisition price for drugs', Journal of Clinical Pharmacy and Therapeutics, 28 73-79 (2003) [C1]
DOI 10.1046/j.1365-2710.2003.00452.x
Citations Scopus - 7Web of Science - 6
2002 Lopert R, Lang DL, Hill SR, Henry DA, 'Differential pricing of drugs: a role for cost-effectiveness analysis?', The Lancet, 359 2105-2107 (2002) [C1]
Citations Scopus - 20Web of Science - 16
Co-authors Mddah01
1999 Whitworth J, Lang DL, Henry DA, 'Cost-effectiveness Analysis in the Treatment of Hypertension: A Medical View', Clinical and Experimental Hypertension, 21(5-6) 999-1008 (1999) [C1]
Co-authors Mddah01
Show 5 more journal articles
Edit

Grants and Funding

Summary

Number of grants 8
Total funding $19,381,559

Click on a grant title below to expand the full details for that specific grant.


20161 grants / $5,680,639

Provision of external evaluation of Pharmaceutical Benefits Advisory Committee (PBAC) and health technology related submissions$5,680,639

Funding body: Department of Health

Funding body Department of Health
Project Team Ms Danielle Lang, Mr Rob Bell, Mr Marc Bevan, Mr Jarrod Bell, Ms Lynn Goon, Doctor Madeleine Hinwood, Doctor Emily Walkom
Scheme Consultancy/Tender
Role Lead
Funding Start 2016
Funding Finish 2020
GNo G1601071
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20141 grants / $53,923

Quotation for the provision of an evaluation of PBS Authority Required medicines using the Deed of Standing Offer SON 1503111 for the supply of PBS Medicines Review services$53,923

Funding body: Department of Health

Funding body Department of Health
Project Team Mr Rob Bell, Ms Danielle Lang, Mr Marc Bevan
Scheme Consultancy/Tender
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1400929
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20131 grants / $20,800

DoH Tender - Pharmaceutical Benefits Scheme (PBS) Medicines Review Panel$20,800

Funding body: Department of Health

Funding body Department of Health
Project Team Mr Marc Bevan, Mr Rob Bell, Ms Danielle Lang
Scheme Consultancy/Tender
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1300519
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20121 grants / $5,826,327

External Evaluation of PBAC Submissions RFT 086/1112 $5,826,327

Funding body: Department of Health

Funding body Department of Health
Project Team Ms Danielle Lang, Mr Barrie Stokes, Mr Marc Bevan, Mr Rob Bell, Mrs Feili Zhao
Scheme Consultancy/Tender
Role Lead
Funding Start 2012
Funding Finish 2016
GNo G1101212
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20081 grants / $4,534,474

External Evaluation of PBAC Submissions RFT 360/0708$4,534,474

Funding body: Department of Health

Funding body Department of Health
Project Team Dr JANE Robertson, Ms Danielle Lang, Mr Rob Bell, Mr Marc Bevan
Scheme Consultancy/Tender
Role Investigator
Funding Start 2008
Funding Finish 2012
GNo G0189557
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20051 grants / $3,221,378

External Evaluation of PBAC Submissions RFP 163/0304$3,221,378

Funding body: Commonwealth Department of Health & Aged Care

Funding body Commonwealth Department of Health & Aged Care
Project Team Ms Danielle Lang, Mr Barrie Stokes, Dr JANE Robertson
Scheme Consultancy/Tender
Role Lead
Funding Start 2005
Funding Finish 2008
GNo G0184477
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20041 grants / $1,066

2nd International Conference on Improving Use of Medicines (ICIUM2004), 30 March - 2 April 2004, Thailand$1,066

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Ms Danielle Lang
Scheme Travel Grant
Role Lead
Funding Start 2004
Funding Finish 2004
GNo G0183884
Type Of Funding Internal
Category INTE
UON Y

20001 grants / $42,952

Local evaluation of the after hours primary medical care trial at Maitland Hospital.$42,952

Funding body: Hunter Urban Division of General Practice

Funding body Hunter Urban Division of General Practice
Project Team Conjoint Professor Dianne O'Connell, Ms Danielle Lang, Ms B Pekarsky
Scheme Research Grant
Role Investigator
Funding Start 2000
Funding Finish 2000
GNo G0180200
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y
Edit

Ms Danielle Lang

Positions

Research Academic
School of Medicine and Public Health
Faculty of Health and Medicine

Senior Lecturer
School of Medicine and Public Health
Faculty of Health and Medicine

Focus area

Clinical Pharmacology and Clinical Toxicology

Contact Details

Email danielle.lang@newcastle.edu.au
Phone (02) 4921 1276
Fax (02) 4960 2088

Office

Room NM2-545
Building Calvary Mater Newcastle Level 5 - New Med 2
Location Mater Hospital

,
Edit